Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 462.77M P/E - EPS this Y 12.70% Ern Qtrly Grth -
Income -202.11M Forward P/E -3.15 EPS next Y 17.40% 50D Avg Chg -22.00%
Sales 3.64M PEG -0.04 EPS past 5Y - 200D Avg Chg -19.00%
Dividend N/A Price/Book 4.07 EPS next 5Y 54.70% 52W High Chg -50.00%
Recommedations 2.00 Quick Ratio 11.21 Shares Outstanding 361.49M 52W Low Chg 11.00%
Insider Own 1.15% ROA -35.69% Shares Float 182.14M Beta 1.29
Inst Own 79.24% ROE -94.81% Shares Shorted/Prior 26.63M/24.53M Price 1.89
Gross Margin - Profit Margin - Avg. Volume 2,655,380 Target Price 6.20
Oper. Margin -3,360.90% Earnings Date Nov 6 Volume 1,578,230 Change -2.58%
About Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Lexicon Pharmaceuticals, Inc. News
11/22/24 Lexicon Pharmaceuticals to Cut 60% of Workforce
11/22/24 Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA
11/22/24 Lexicon to disband sales team, lay off 60% of staff
11/20/24 Lexicon Appoints Ivan H. Cheung to Board of Directors
11/18/24 Lexicon Pharmaceuticals (NASDAQ:LXRX investor three-year losses grow to 80% as the stock sheds US$107m this past week
11/14/24 Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations is Among Four Lexicon-Supported Presentations at the American Heart Association’s (AHA) Sessions 2024 in Chicago
11/13/24 Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ...
11/12/24 Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Lags Revenue Estimates
11/12/24 Lexicon: Q3 Earnings Snapshot
11/12/24 Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
11/06/24 Lexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare Conference
11/06/24 A diabetes drug, twice rejected, stumbles again — but its developer persists
11/05/24 Published Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People With Type 1 Diabetes and Chronic Kidney Disease
11/05/24 Lexicon Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 12, 2024
11/04/24 Lexicon to Present Preclinical IN VIVO Efficacy Data Demonstrating Ability of New Investigational Compound to Enhance and Maintain Semaglutide-Promoted Weight Loss
11/01/24 Sector Update: Health Care Stocks Rise Late Afternoon
11/01/24 Top Midday Decliners
10/31/24 Lexicon Announces Outcome of FDA Advisory Committee for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease
10/27/24 FDA Endocrinologic and Metabolic Drugs Advisory Committee to hold a meeting
08:00 AM New Analysis of Phase 3 Data Demonstrating Renal Protective Benefits of Sotagliflozin to be Presented at ASN Kidney Week 2024
LXRX Chatroom

User Image Themedstock Posted - 46 minutes from now

$LXRX On FDA phase 2 studies it seems there are no major lifethreatening AEs. If lx9211 has a noticeable effect on patients' neuropathic pain reliefs , fda phase 3 will easily be passed. When it is commercialized it can be applied on whole different kinds of neuropathis like zoster / diabetes etc. Currently in practice neuropsychiatric durgs are normally used for these disease (+ nerve blocks ) but when its passed it will become a commonly used treatment of options. Hope we dont see AEs equivalent to imperfa's euglycemic DKA from Lx9211

User Image Robyurii Posted - 7 hours ago

$LXRX Surprised, but not disappointed at the announcement they are shutting down commercialization. My guess...they are going to throw everything into boosting sp over the next six months in preparation for a BO. Recall that Exton mentioned some of the big pharma players had a lot of interest in LX9211 2b results coming up next quarter. Pure speculation on my part, but if 9211 results are promising, I wouldn't be surprised to see a BO offer by mid-2025. Just going to hold and wait and see.

User Image HumbleTrader187 Posted - 7 hours ago

$LXRX looking great for next week! new blood on the board, major cost savings, solid pipeline. if nothing else, this is worth way more than A DOLLAR ffs.

User Image goBIGRgoHOME Posted - 7 hours ago

$LXRX Like $QMCO $XCUR

User Image MYFLAUT Posted - 8 hours ago

$LXRX To the left of the reshare button in commets button mine will not let me read ! what am i doing wrong ?

User Image bioman2024 Posted - 9 hours ago

$LXRX …I have had the pleasure of having 10 baggers before. I also have had plenty of losers. I am definately NOT saying this will be a ten bagger but 10 baggers can be born from the likes of these. Just saying.

User Image 123rickiek Posted - 10 hours ago

$LXRX I bet once they announce partnership that zynquista will get approved by the FDA .

User Image Jas7235355 Posted - 10 hours ago

$LXRX Imo… they have a ruby in one drug (now) and a diamond coming next year. BP will want now snd future together . BO not less than $10. Ive seen other drugs with less go about $15-20 .

User Image Twenerz Posted - 10 hours ago

$LXRX @Beebomb The last two or three calls have discussed partnerships being sought. Certainly, the partner gets a significant slice of the pie, but I’ve always believed that was the best option for them. BP has the infrastructure and manpower resources along with the access. it’s extremely difficult for small operations to get traction even in markets less crowded. I’ve suspected for a long time this was coming, and I think it makes business sense. They will partner for 9211 and maybe even Sota and depending upon how other ongoing studies start reading out, if positive, will likely ultimately be acquired because that would make more financial sense for the partner. At least that’s how I’ve always seen this to play out assuming the science succeeds. So far, it really has with the sale of their first asset and the approval of sota. Certainly no guarantee of future success but it seems the work they did early on has increased the probability of positive results. We will see…

User Image goBIGRgoHOME Posted - 10 hours ago

$LXRX Setting up for big run. 💥💥🚀🚀 like $SKK $QMCO $XCUR 💪👌

User Image gucag006 Posted - 11 hours ago

$LXRX Between $3.5 and $4.5.

User Image Dooright Posted - 11 hours ago

$LXRX I wonder when (the date of receipt of) the letter from the FDA was received? Just curious. If I had a gun pointed at my head, I never would have predicted today’s news and price action of our stock that followed. I’d be dead with a hole in my cranium! You just can’t make this stuff up! 😆 Doc C. 🤓

User Image Dooright Posted - 11 hours ago

$LXRX Doubtful at best. Doc C. 🤓

User Image gucag006 Posted - 11 hours ago

$LXRX For a BO partner, a.k.a. BP, things could get a little more complicated. First, the rights of Viatris need to be dealt with. Most likely the BO partner would buy the rights back as a whole, or countries by countries. No matter what Viatris would be a bigger winner before anyone else. Then the BO price. Unless RD has a change of heart, he won't let go for less than 5x of his base, and his base is .....

User Image Jas7235355 Posted - 11 hours ago

$LXRX … if they can read the FDA has to approve some if it

User Image nsheller44 Posted - 11 hours ago

$LXRX How likely is it that the FDA approves the drug in December 20th?

User Image Jas7235355 Posted - 11 hours ago

$LXRX … and what do you think Ray will agree SP to be at BO? I think originally someone said he wanted 2X his average?

User Image blaack_rules Posted - 11 hours ago

$LXRX Need to remember that the easiest way for Debbane to exit his huge position is through a buyout. He cannot sell his stock into the open market. It could happen after the results of the 9211 2b trial are reported. He has better luck with fast food startup companies. I am looking at 2025 as the end of Lexicon.

User Image Dooright Posted - 12 hours ago

$LXRX Holy crap! Didn’t close at the hod, but I’ll take it with no complaints. Something big is brewing. Eventually, we’ll know what’s in the cauldron! 😆👍😜 Doc C. 🤓

User Image gucag006 Posted - 12 hours ago

$LXRX For a commercialization partner, it is relatively simple. The partnership money goes to the company, and we SHs are at the mercy of the worldwide royalties from Inpefa for now, HCM and LX9212 a little later, and LX9851 much later. There is no overhead with royalty, so its valuation will be based on profits and net margin with COGS being the selling price to the partner. So, the COGS is 100% guaranteed and recovered, which leaves them with only R&D expenses, and the net profit is royalty minus R&D. If the drugs sell well, a decent net margin could support a handsome valuation.

User Image KurwaMac Posted - 12 hours ago

$LXRX partnership for inpefa soon, good results 1st qt 25 results in BO

User Image Marta22 Posted - 12 hours ago

$LXRX Fomo from Monday

User Image Trade_Bot Posted - 12 hours ago

$LXRX Very difficult couple weeks. Seems bottom is in and heading in a solid direction - great volume and inflowS. Hopefully continued crawl back next week. A US/EU partner will definately rip it. Give Viatris deal, news this morning, is probably closer then we think. Have a great weekend!

User Image Stmkr Posted - 12 hours ago

$LXRX What is the bear thesis now??

User Image HorizonBull Posted - 12 hours ago

$LXRX add and relax

User Image liloleme4 Posted - 12 hours ago

$LXRX I added more. Couldn't help myself. Things are looking good and the price is so tantalizing

User Image Kentucky123 Posted - 12 hours ago

$LXRX Great Volume.

User Image Nostradastock Posted - 12 hours ago

$LXRX With this Board I wouldn't be surprised if by mid-December we already had the name of the partnership Bio or merger.

User Image Stmkr Posted - 12 hours ago

$LXRX is finally doing what should have done a long time ago. Much better cash runway now + partnership potential soon + promising pipeline

User Image Stmkr Posted - 12 hours ago

$LXRX Great decisions by LXRX today. it is getting much more interesting now

Analyst Ratings
HC Wainwright & Co. Buy Sep 27, 24
HC Wainwright & Co. Buy Sep 11, 24
HC Wainwright & Co. Buy Sep 3, 24
HC Wainwright & Co. Buy Aug 21, 24
HC Wainwright & Co. Buy Aug 13, 24
HC Wainwright & Co. Buy Aug 2, 24
HC Wainwright & Co. Buy Jul 16, 24
HC Wainwright & Co. Buy Jun 24, 24
HC Wainwright & Co. Buy Jun 21, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
COATS LONNEL Chief Executive Offi.. Chief Executive Officer Nov 10 Buy 1.01 10,000 10,100 824,359 11/13/23
WADE JEFFREY L President and CFO President and CFO Sep 14 Buy 1.38 10,000 13,800 264,341 09/14/23
Invus US Partners LLC Director Director Aug 05 Buy 2.50 147,390 368,475 5,451,204 08/09/22
Artal International S.C.A. Director Director Aug 05 Buy 2.50 2,426,070 6,065,175 50,859,331 08/09/22